Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2
Breast Cancer · 2025-11 · 32 (6) · 1472-1479
DOI: 10.1007/s12282-025-01740-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Breast Cancer, online erschienen am 02.07.2025. Verfasst von Ryoko Semba und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Juntendo University Nerima Hospital, Takanodai 3-1-10, Nerima-Ku, Tokyo, 177-8521, Japan. Hauptthemen laut MEDLINE: Germ-Line Mutation, BRCA2 Protein, Breast Neoplasms, BRCA1 Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
While patients with hereditary breast and ovarian cancer with germline double heterozygosity (GDH) for BRCA1 and BRCA2 are rare, carcinogenesis in these cases remains unclear. We examined two-hit events of heterochronous bilateral breast cancers in a patient with GDH for BRCA1 and BRCA2 . A 65-year-old woman developed right breast cancer (triple-negative type) at the age of 49 and left breast cancer (triple-negative type) at 55. Family history indicated that multiple relatives on her mother’s side also developed breast cancer. BRCA1/2 genetic testing (BRACAnalysis®) showed that she had variants in both the BRCA1 and BRCA2 ( BRCA1 :c.5193 + 2dup, BRCA2 :c.6952C > T/p.Arg2318Ter). According to the data from the test, the former was interpreted as likely pathogenic at Myriad Inc. Further examination regarding two-hit events in her bilateral breast cancers was obtained by somatic mutation analysis using DNA isolated from cut slide specimens of formalin-fixed and paraffin-embedded tumor samples. We first confirmed the pathogenicity of the BRCA2 variant by detecting unusual splicing of BRCA2 that entirely skipped exon 19 using cultured T cells of the proband. Loss of heterozygosity in BRCA1 was observed in her right breast cancer. On the other hand, a somatic nonsense pathogenic variant in BRCA2 (variant allele frequency = 15%) and a two-hit event in APC (VAF = 80%) were also found in her left breast cancer. These data provide evidence of different carcinogenesis between left and right breast cancer. Clinical and pathogenic characteristics of cancers with GDH for BRCA1 and BRCA2 depend on the genes somatically mutated in wild alleles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Juntendo University Nerima Hospital, Takanodai 3-1-10, Nerima-Ku, Tokyo, 177-8521, Japan.
- Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Clinical Genetics, Aizawa Hospital, Matsumoto, Japan.
- Department of Breast and Thyroid Surgery, Aizawa Hospital, Matsumoto, Japan.
- Department of Breast and Endocrine Surgery, Suwa Red Cross Hospital, Suwa, Japan.
- Department of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Zitieren
APA
Semba, R., Eguchi, H., Takatsu, M., Hashizume, T., Moteki, H., Maeno, K., Murakami, F., Watanabe, J., Kutomi, G., & Arai, M. (2025). Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2. Breast Cancer, 32(6), 1472-1479. https://doi.org/10.1007/s12282-025-01740-4
Vancouver
Semba R, Eguchi H, Takatsu M, Hashizume T, Moteki H, Maeno K, et al. Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2. Breast Cancer. 2025;32(6):1472-1479. doi:10.1007/s12282-025-01740-4
BibTeX
@article{Semba2025,
author = {Semba, Ryoko and Eguchi, Hidetaka and Takatsu, Mizuki and Hashizume, Toko and Moteki, Hideaki and Maeno, Kazuma and Murakami, Fumi and Watanabe, Junichiro and Kutomi, Goro and Arai, Masami},
title = {Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2},
journal = {Breast Cancer},
year = {2025},
volume = {32},
number = {6},
pages = {1472--1479},
doi = {10.1007/s12282-025-01740-4}
}
EUVIMED